Analytic Investors’s Haemonetics HAE Stock Holding History

Analytic Investors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-6,697	Closed	-$216K	–	648
2015 Q3	$216K	Sell	6,697 -2,483	-27%	-$93.4K	﹤0.01%	525
2015 Q2	$380K	Hold	9,180	–	–	0.01%	490
2015 Q1	$413K	Buy	9,180 +1,102	+14%	+$46.1K	0.01%	463
2014 Q4	$302K	Buy	+8,078	New	+$296K	﹤0.01%	473

Other funds holding HAE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.3B AUM 29.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Analytic Investors's HAE Position: Q4 2015 in Review

Analytic Investors sold out of Haemonetics (HAE) in Q4 2015, closing a stake of 6,697 shares — an estimated $216K sold.

Analytic Investors first reported a position in HAE in Q4 2014 and held it in 4 quarters. The position peaked at $413K in Q1 2015. 164 funds tracked by Wall St. Rank hold HAE as of Q4 2015.

Analytic Investors reported no remaining Haemonetics position as of Q4 2015 after selling out during the quarter.
Analytic Investors sold 6,697 Haemonetics shares in Q4 2015, an estimated $216K.
Analytic Investors first reported a position in Haemonetics in Q4 2014 and held it in 4 quarters.
Analytic Investors's Haemonetics position peaked at $413K in Q1 2015.
164 funds tracked by Wall St. Rank held Haemonetics as of Q4 2015.

Based on Analytic Investors's 13F filing for Q4 2015, filed 12 Feb 2016.